New York Life Investment Management LLC Grows Stock Holdings in Encompass Health Co. (NYSE:EHC)

New York Life Investment Management LLC increased its holdings in shares of Encompass Health Co. (NYSE:EHC) by 6.6% in the 4th quarter, HoldingsChannel reports. The firm owned 11,839 shares of the company’s stock after acquiring an additional 734 shares during the quarter. New York Life Investment Management LLC’s holdings in Encompass Health were worth $790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James & Associates raised its stake in shares of Encompass Health by 5.7% during the 3rd quarter. Raymond James & Associates now owns 164,936 shares of the company’s stock valued at $11,077,000 after buying an additional 8,952 shares during the last quarter. Verdence Capital Advisors LLC lifted its holdings in Encompass Health by 7.1% in the third quarter. Verdence Capital Advisors LLC now owns 5,580 shares of the company’s stock valued at $375,000 after acquiring an additional 370 shares during the period. Strs Ohio boosted its position in Encompass Health by 8.5% in the 3rd quarter. Strs Ohio now owns 153,252 shares of the company’s stock worth $10,292,000 after purchasing an additional 11,975 shares in the last quarter. Park Avenue Securities LLC acquired a new stake in shares of Encompass Health during the 3rd quarter worth approximately $298,000. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Encompass Health by 5.3% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,288,858 shares of the company’s stock valued at $86,560,000 after purchasing an additional 64,442 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Price Performance

NYSE:EHC opened at $85.32 on Thursday. The stock has a 50 day moving average of $79.54 and a two-hundred day moving average of $71.95. Encompass Health Co. has a 12 month low of $57.55 and a 12 month high of $86.60. The firm has a market cap of $8.59 billion, a P/E ratio of 23.06, a price-to-earnings-growth ratio of 1.30 and a beta of 0.92. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the prior year, the company earned $0.88 EPS. The firm’s revenue was up 13.4% compared to the same quarter last year. On average, analysts expect that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Monday, July 1st will be issued a $0.15 dividend. The ex-dividend date is Friday, June 28th. This represents a $0.60 dividend on an annualized basis and a yield of 0.70%. Encompass Health’s payout ratio is 16.22%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on EHC. Stephens reissued an “overweight” rating and set a $85.00 price target on shares of Encompass Health in a report on Tuesday, January 16th. William Blair restated an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Barclays lifted their price target on Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Finally, Truist Financial boosted their price objective on Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Friday, February 9th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $90.29.

Insider Transactions at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 44,976 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the sale, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at approximately $46,139,740.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Greg D. Carmichael purchased 2,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was acquired at an average price of $83.73 per share, with a total value of $167,460.00. Following the purchase, the director now directly owns 17,050 shares in the company, valued at approximately $1,427,596.50. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Mark J. Tarr sold 44,976 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the sale, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.